Bladder cancer

GEC-ESTRO Handbook: https://user-swndwmf.cld.bz/21-Urinary-Bladder-Cancer-GEC-ESTRO-Handbook-of-Brachytherapy

Voskuilen CS, Bosschieter J, van Werkhoven E, Hendricksen K, Vis AN, Witteveen T, Pieters BR, Burger M, Bex A, van der Poel HG, Moonen LM, Horenblas S, Nieuwenhuijzen JA, van Rhijn BWG. Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiother Oncol. 2019 Dec;141:130-136. doi: 10.1016/j.radonc.2019.09.026.

Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007.

Slevin F, Sethugavalar B, Al-Qaisieh B, Bownes P, Mason J, Smith J, Bottomley D, Henry AM. Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. J Contemp Brachytherapy. 2020 Dec;12(6):540-546. doi: 10.5114/jcb.2020.101686.

Joshua Mason, Ann Henry, Peter Bownes. Error detection thresholds for routine real time in vivo dosimetry in HDR prostate brachytherapy. Radiotherapy and Oncology 2020: 149:38-43

Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Wilkinson C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM. A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clin Transl Radiat Oncol. 2019 Oct 14;20:1-8. doi:10.1016/j.ctro.2019.10.00.

Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal High-Dose-Rate Brachytherapy-An Alternative Organ-Preserving Approach for Primary Male Urothelial Carcinoma With Panurethral Involvement. Pract Radiat Oncol. 2020 Jan-Feb;10(1):e53-e56. doi: 10.1016/j.prro.2019.08.013.